Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02974621 · ClinicalTrials.gov registry record · Phase 2
Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma
A Phase 2 study of Recurrent Glioblastoma, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 20
- Study locations
NCT02974621 is a Phase 2 study of Recurrent Glioblastoma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 70 participants, roughly in line with the 68-participant average among 62 other Recurrent Glioblastoma trials with a reported enrollment target. The trial reports 20 study locations across 7 states.
The verdict
NCT02974621, a Phase 2 study of Recurrent Glioblastoma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 20
- Study locations
Study Summary
This randomized phase II trial studies how well cediranib maleate and olaparib work compared to bevacizumab in treating patients with glioblastoma that has come back (recurrent). Cediranib maleate and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as bevacizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Conditions Studied
Interventions
- DRUG Olaparib
- BIOLOGICAL Bevacizumab
- DRUG Cediranib
- DRUG Cediranib Maleate
Study Locations (20)
Connecticut
- Smilow Cancer Hospital-Derby Care Center - Derby
- Smilow Cancer Hospital Care Center-Fairfield - Fairfield
- Smilow Cancer Hospital Care Center - Guilford - Guilford
- Smilow Cancer Hospital Care Center at Saint Francis - Hartford
- Smilow Cancer Center/Yale-New Haven Hospital - New Haven
- Yale University - New Haven
- Smilow Cancer Hospital-Orange Care Center - Orange
- Smilow Cancer Hospital-Torrington Care Center - Torrington
- Smilow Cancer Hospital Care Center-Trumbull - Trumbull
- Smilow Cancer Hospital-Waterbury Care Center - Waterbury
- Smilow Cancer Hospital Care Center - Waterford - Waterford
Missouri
- Siteman Cancer Center at Saint Peters Hospital - City of Saint Peters
- Siteman Cancer Center at West County Hospital - Creve Coeur
- Washington University School of Medicine - St Louis
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
- Dana-Farber Cancer Institute - Boston
California
- UC San Diego Moores Cancer Center - La Jolla
Colorado
- UCHealth University of Colorado Hospital - Aurora
Florida
- Moffitt Cancer Center - Tampa
Kentucky
- University of Kentucky/Markey Cancer Center - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2017-12-07 |
| Est. Completion | 2026-07-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02974621
The ClinicalTrials.gov registry entry for NCT02974621 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 68-participant average among 62 other Recurrent Glioblastoma trials with a reported enrollment target. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Recurrent Glioblastoma appearing as the primary indexed condition, and to 4 interventions - of which Olaparib is the first listed.
NCT02974621 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Connecticut, Missouri, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02974621 about?
NCT02974621 is a clinical study titled "Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma". This randomized phase II trial studies how well cediranib maleate and olaparib work compared to bevacizumab in treating patients with glioblastoma that has come back (recurrent). Cediranib maleate and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth....
What is the current status of trial NCT02974621?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2017-12-07. Estimated completion is 2026-07-17.
What conditions does trial NCT02974621 study?
This clinical trial studies the following conditions: Recurrent Glioblastoma.
What interventions are being tested in trial NCT02974621?
The interventions under investigation include: Olaparib (DRUG), Bevacizumab (BIOLOGICAL), Cediranib (DRUG), Cediranib Maleate (DRUG).
Who is sponsoring clinical trial NCT02974621?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02974621 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Florida, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Surgical Pembro +/- Olaparib w TMZ for rGBM
RECRUITING · Phase 2
-
A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial
RECRUITING · Phase 2
-
Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma
RECRUITING · Phase 2
-
OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial
RECRUITING · Phase 2
-
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan in Recurrent Glioblastoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.